1310404-86-4

Usage

Uses

Used in Organic Synthesis:
3-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methoxy)phenylboronic acid is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, such as Suzuki-Miyaura cross-coupling reactions. This makes it a useful building block for the creation of complex organic molecules.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 3-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methoxy)phenylboronic acid is used as a key intermediate in the development of pharmaceutical compounds. Its unique structure and functional groups contribute to the design and synthesis of novel drug candidates with potential therapeutic applications.
Used in Chemical Research:
3-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methoxy)phenylboronic acid is utilized in chemical research to explore its properties and potential applications. Its versatility in participating in various chemical reactions and its unique structural features make it an interesting subject for further investigation and development in the field of chemistry.

Upstream product

• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 594823-67-3 (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bromobenzene) 
• 591-20-8 3-Bromophenol 
• 180847-24-9 tert-butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1595291-30-7 tert-butyl 5-(tert-butoxycarbonyl(2-(3-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)phenyl)pyrimidin-4-yl)amino)-1H-indazole-1-carboxylate 
• 1595289-72-7 N-(2-(3-(piperidin-4-ylmethoxy)phenyl)pyrimidin-4-yl)-1H-indazol-5-amine 

Relevant academic research and scientific papers

Chemoselective, Scalable Nickel-Electrocatalytic O-Arylation of Alcohols

The formation of aryl-alkyl ether bonds through cross coupling of alcohols with aryl halides represents a useful strategic departure from classical SN2 methods. Numerous tactics relying on Pd-, Cu-, and Ni-based catalytic systems have emerged over the past several years. Herein we disclose a Ni-catalyzed electrochemically driven protocol to achieve this useful transformation with a broad substrate scope in an operationally simple way. This electrochemical method does not require strong base, exogenous expensive transition metal catalysts (e.g., Ir, Ru), and can easily be scaled up in either a batch or flow setting. Interestingly, e-etherification exhibits an enhanced substrate scope over the mechanistically related photochemical variant as it tolerates tertiary amine functional groups in the alcohol nucleophile.

TREATMENT OF GVHD

The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD ( cGVHD) using compounds having the formulae l-XXV, as set forth herein.

TREATMENT OF OCULAR DISORDERS

The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a ROCK2 inhibitor and an angiogenesis inhibitor. In certain embodiments, the ROCK2 inhibitor is ROCK2 selective. In certain embodiments, the angiogenesis inhibitor is a VEGF antagonist, for example, and VEGFR2 antibody.